MINERALYS THERAPEUTICS ($MLYS) posted quarterly earnings results for Q2 2026 on Tuesday, August 11th. The company reported earnings of -$2.85 per share, missing estimates of -$0.55 by $2.30. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market close: -4.32%
You can see Quiver Quantitative's $MLYS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MINERALYS THERAPEUTICS Insider Trading Activity
MINERALYS THERAPEUTICS insiders have traded $MLYS stock on the open market 41 times in the past 6 months. Of those trades, 2 have been purchases and 39 have been sales.
Here’s a breakdown of recent trading of $MLYS stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 2 purchases buying 369,000 shares for an estimated $8,762,797 and 0 sales.
- JON CONGLETON (Chief Executive Officer) has made 0 purchases and 7 sales selling 176,430 shares for an estimated $4,644,543.
- DAVID MALCOM RODMAN (Chief Medical Officer) has made 0 purchases and 28 sales selling 135,786 shares for an estimated $3,668,226.
- ERIC WARREN (Chief Commercial Officer) has made 0 purchases and 2 sales selling 111,562 shares for an estimated $2,896,207.
- DAPHNE KARYDAS has made 0 purchases and 2 sales selling 6,000 shares for an estimated $150,000.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
MINERALYS THERAPEUTICS Hedge Fund Activity
We have seen 109 institutional investors add shares of MINERALYS THERAPEUTICS stock to their portfolio, and 96 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,574,801 shares (+328.3%) to their portfolio in Q1 2026, for an estimated $69,751,359
- HOLOCENE ADVISORS, LP removed 1,602,035 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $43,399,128
- BLACKROCK, INC. added 1,405,456 shares (+31.4%) to their portfolio in Q2 2026, for an estimated $37,919,202
- SAMLYN CAPITAL, LLC removed 1,304,932 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $35,350,607
- STATE STREET CORP added 1,205,696 shares (+41.1%) to their portfolio in Q2 2026, for an estimated $32,529,678
- CAPITAL INTERNATIONAL INVESTORS removed 1,163,290 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $31,513,526
- ORBIMED ADVISORS LLC added 1,072,500 shares (+109.4%) to their portfolio in Q1 2026, for an estimated $29,054,025
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
MINERALYS THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $MLYS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 04/27/2026
To track analyst ratings and price targets for MINERALYS THERAPEUTICS, check out Quiver Quantitative's $MLYS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
